Flu Platform

FLUAllaChem together with ASAVI (www.asavillc.com) has been developing novel small molecules with superior efficacy, and safety properties as compared to competitors’ first in class compounds.

Allachem’s and ASAVI’s per oral drug candidates AV5075C and AV5080 are now in pre-clinical development for the treatment of flu.

Download AV5080: a new highly effective neuraminidase inhibitor Documentation

FLU

AV5080: a new highly effective neuraminidase inhibitor